Department of Gastroenterology, Xiangya Hospital of Central South University, Changsha, Hunan Province, 410008, China.
Exp Mol Pathol. 2011 Dec;91(3):745-52. doi: 10.1016/j.yexmp.2011.07.007. Epub 2011 Aug 7.
Clinical trials of suicide gene therapy have achieved limited success, which suggests a need for improvement. Angiogenesis plays a crucial role in the progression of cancers, which is greatly regulated by vascular endothelial growth factor (VEGF).The current study was designed to evaluate the anti-tumor effects of VEGF siRNA in combination with fusion suicide gene yCDglyTK. Introduction of a VEGF-targeted small hairpin RNA (shVEGF) to CDTK/5-FC system could induce cell apoptosis more effectively and decrease micro vessel density in xenograft tissue, thus resulted in a significant tumor growth delay in SGC7901 xenografts. These findings for the first time suggest the potential of combination gene therapy using suicide gene therapy and anti-angiogenesis gene therapy.
临床试验的自杀基因治疗取得了有限的成功，这表明需要改进。血管生成在癌症的进展中起着至关重要的作用，这是由血管内皮生长因子（VEGF）调节的。本研究旨在评估 VEGF siRNA 与融合自杀基因 yCDglyTK 联合的抗肿瘤作用。将 VEGF 靶向小发夹 RNA（shVEGF）导入 CDTK/5-FC 系统可以更有效地诱导细胞凋亡，并降低异种组织中的微血管密度，从而导致 SGC7901 异种移植物的肿瘤生长显著延迟。这些发现首次表明了自杀基因治疗和抗血管生成基因治疗联合应用的组合基因治疗的潜力。
